Institute for State Control of Veterinary Biologicals and Medicines
Hudcova 56a
621 00 Brno
Czech Republic
(Reference Member State)

MUTUAL RECOGNITION PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Ketoprofen Bioveta 100 mg/ml solution for injection

MODULE 1

PRODUCT SUMMARY

EU Procedure number	CZ/V/0183/001/MR
Name, strength and pharmaceutical form	Ketoprofen Bioveta 100 mg/ml solution for injection
Applicant	Bioveta, a.s. Komenského 212 683 23 Ivanovice na Hané Czech Republic
Active substance(s)	Ketoprofen
ATCvet code	QM01AE03
Target species	Cattle, horses, pigs
Indication for use	Cattle - Alleviation of inflammation and pyrexia associated with respiratory infections, in combination with antimicrobial treatment if necessary. - Alleviation of inflammation, pyrexia and pain in acute clinical mastitis, in combination with antimicrobial treatment if necessary. - Alleviation of inflammation and pain associated with udder oedema following calving. - Alleviation of inflammation, pyrexia and pain associated with musculoskeletal disorders (e.g. supportive treatment of post-partum paresis, lameness, arthritis, traumatic injuries and dystocia). Horses - Alleviation of inflammation and pain associated with osteoarticular and musculoskeletal disorders (lameness of traumatic origin, arthrosis, arthritis, osteitis, tendinitis, bursitis, navicular bone inflammation, laminitis, myositis and post-operative inflammation). - Alleviation of pain associated with colic. - Alleviation of pyrexia. Pigs

	- Alleviation of inflammation and pyrexia associated with Metritis Mastitis Agalactia syndrome (MMA) and in case of respiratory infections, in combination with antimicrobial treatment if necessary.

MODULE 2

The Summary of Product Characteristics (SPC), the labelling and package leaflet for this veterinary medicinal product (VMP) is available in the Union Product Database (UPD).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Art. 18 – Generic application
Date of completion of the original mutual recognition procedure	18/10/2023
Date product first authorised in the Reference Member State (MRP only)	21/09/2020
Concerned Member States for original procedure	AT, BG, EL, FR, HU, PL, RO, SK

I. SCIENTIFIC OVERVIEW

***For public assessment reports for the first authorisation in a range**:*

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species; the reactions observed are indicated in the SPC.
The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Qualitative and quantitative particulars

The veterinary medicinal product Ketoprofen Bioveta is an aqueous solution for injection containing Ketoprofen as the active substance at concentration 100 mg/mL and excipients L-arginine as solubiliser and for pH adjustment, Citric acid monohydrate for pH adjustment and Benzyl alcohol as a preservative. The solution is filled into 100mL glass vials type II and closed with rubber stopper and an aluminium flip-off cap.

The product is developed as a generic to Ketofen 10% (w/v) solution for injection marketed by Ceva Santé Animale, which was first authorised in CZ on 29/12/1997. Ketoprofen Bioveta contains the same excipients in very similar amount as the reference formulation. Benzylalcohol is used as preservative and its efficacy is demonstrated.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.
The manufacturing process is standard and consists of simple preparation of the bulk solution that is followed by filtration, filling and sealing of vials and terminal sterilization using standard Ph. Eur. moist-heat conditions. The detailed process description is provided for commercial batch size including process conditions and controls. Satisfactory process validation studies are performed on three commercial batches.

C. Control of Starting Materials

The active substance is Ketoprofen, an established substance described in the Ph. Eur. monograph. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Certificates of suitability issued by the EDQM have been provided.

All excipients are described in the Ph. Eur. monographs and they are controlled accordingly. Additional controls are established, taking into account the final use of the excipients in sterile parenteral product.

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

Satisfactory quality controls are given for the container-closure system. The vials and stoppers comply with the relevant Ph. Eur. chapters.

D. Control on intermediate products

Not applicable.

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification and their limits, have been justified and are considered appropriate to adequately control the quality of the veterinary medicinal product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

F. Stability

Stability data on the active substances are covered by the relevant certificates of suitability issued by the EDQM.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life which is 2 years when

stored under the approved conditions (Protect from frost. Keep the injection vial in the carton in order to protect from light.).

The claim of a 28 days after first opening the immediate packaging is based on the demonstration of stability for a batch broached and stored 28 days at 25 °C ± 2 °C, protected from light.

G. Other Information

Not applicable.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

As this is a generic application according to Article 18, results of pharmacological and toxicological tests are not required.

Warnings and precautions as listed on the product literature are adequate to ensure safety of the product to users, the environment and consumers.

User Safety

The applicant has provided a user safety assessment in compliance with the relevant guideline. Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines.

Phase I:

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the veterinary medicinal product will be used to treat a small number of animals.

III.B Residues documentation

Residue Studies

The application has been submitted in accordance with article 18 of Regulation (EU) 2019/6 as amended, a so called the generic application. The reference product is Ketofen 10% (w/v) solution for injection marketed by Ceva Santé Animale, which was first authorised in CZ on 29/12/1997 on the basis of full application.
The product contains the same active substance in the same concentration and excipients as the reference product.

MRLs

Ketoprofen is included in Table 1 of the Annex to Commission Regulation (EU) No 37/2010 as follows:

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs (µg/kg)	Target tissues	Other provisions
Ketoprofen	NOT APPLICABLE	Bovine, porcine, *Equidae*	No MRL required	NOT APPLICABLE	NO ENTRY

All excipients (arginine, benzyl alcohol, citric acid, aqua) are either allowed substances for which Table 1 of the Annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used in this product.

Withdrawal Periods

The same withdrawal periods as are authorised for the reference product have been mentioned in section 3.12 of the SPC:

Cattle: Meat and offal: after intramuscular administration: 4 days
after intravenous administration: 1 day
Milk: zero hours.
Pigs: Meat and offal: 4 days
Horses: Meat and offal: 1 day
Milk: Not authorised for use in horses producing milk for human consumption.

IV. CLINICAL ASSESSMENT (EFFICACY)

As this is a generic application according to Article 18 of Regulation (EU) 2019/6 as amended, and an exemption from bioequivalence studies according to the section 7 of the CVMP Guideline on the conduct of bioequivalence studies for veterinary medicinal products (EMA/CVMP/016/2000-Rev.4) was accepted, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

Quality changes

Summary of change (Application number)	Section updated in Module 3	Approval date
Update of the CEP (VNRA/NP)	N/A	June 2023